Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XVII.e

Pneumocystis jiroveci pneumonia

Publications

Haddad TM, Vallabhajosyula S, Nawaz MS, Vivekanandan R

Fatal Pneumocystis jirovecii pneumonia in a HIV-negative adult.

BMJ case reports. 2015;2015

Hagiya H, Miyake T, Kokumai Y, Murase T, Kuroe Y, Nojima H, Sugiyama J, Naito H, Hagioka S, Morimoto N

Co-infection with invasive pulmonary aspergillosis and Pneumocystis jirovecii pneumonia after corticosteroid therapy.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2013;19(2):342-7

Yoshida Y, Takahashi Y, Minemura N, Ueda Y, Yamashita H, Kaneko H, Mimori A

Prognosis of pneumocystis pneumonia complicated in patients with rheumatoid arthritis (RA) and non-RA rheumatic diseases.

Modern rheumatology. 2012;22(4):509-14

Toper C, Rivaud E, Daniel C, Cerf C, Parquin F, Catherinot E, Honderlick P, Escande MC, Dreyfus JF, Stern M, Couderc LJ

[Pneumocystis jirovecii pneumonia in non-HIV infected patients: a study of 41 cases].

Revue de pneumologie clinique. 2011;67(4):191-8

Carmona EM, Limper AH

Update on the diagnosis and treatment of Pneumocystis pneumonia.

Therapeutic advances in respiratory disease. 2011;5(1):41-59

Lim KH, Yoon HI, Kang YA, Lee KW, Kim JH, Bang SM, Lee JH, Lee CT, Lee JS

Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab.

The Korean journal of internal medicine. 2010;25(1):86-92

Festic E, Gajic O, Limper AH, Aksamit TR

Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features.

Chest. 2005;128(2):573-9

Pagano L, Fianchi L, Mele L, Girmenia C, Offidani M, Ricci P, Mitra ME, Picardi M, Caramatti C, Piccaluga P, Nosari A, Buelli M, Allione B, Cortelezzi A, Fabbiano F, Milone G, Invernizzi R, Martino B, Masini L, Todeschini G, Cappucci MA, Russo D, Corvatta

Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres.

British journal of haematology. 2002;117(2):379-86

Yale SH, Limper AH

Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy.

Mayo Clinic proceedings. 1996;71(1):5-13